Replies to post #113090 on Biotech Values

[jbog]

so all in all a share price in the 13s strictly from a valuation standpoint (not factoring in other assets) does seem cheap

Wow, have I heard that song before, all the way down from $25. Drug stocks are valued on their future, and while Momenta's seems somewhat nice, it could take years or decades to unravel.

[alertmeipp]

I think the logic could be - after all these dialogues and promises of approval Teva had mentioned about, why still this letter?

If those issues are minor, Teva should have them sorted out already after all these years.

I just think we cannot take the word Minor in face value, like Approvable letter doesn't mean the drug could be ultimately approved.